Earnings Summary

Akebia Therapeutics Inc’s revenue fell -34.96% since last year same period to $40.13Mn in the Q1 2023. On a quarterly growth basis, Akebia Therapeutics Inc has generated -27.28% fall in its revenue since last 3-months.

Akebia Therapeutics Inc’s net profit jumped 58% since last year same period to $-26.22Mn in the Q1 2023. On a quarterly growth basis, Akebia Therapeutics Inc has generated -247.15% fall in its net profits since last 3-months.

Akebia Therapeutics Inc’s net profit margin jumped 35.42% since last year same period to -65.34% in the Q1 2023. On a quarterly growth basis, Akebia Therapeutics Inc has generated -377.38% fall in its net profit margins since last 3-months.

Akebia Therapeutics Inc’s earning per share (EPS) estimates for the current quarter stand at -0.14 - a 6.67% jump from last quarter’s estimates.

Akebia Therapeutics Inc’s earning per share (EPS) estimates for the current year stand at -0.14.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Akebia Therapeutics Inc’s return on assets (ROA) stands at -0.01.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Akebia Therapeutics Inc’s return on equity (ROE) stands at -9.58.